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A growing set of observations points to mitochondrial dysfunction, iron accumulation,
oxidative damage and chronic inﬂammation as common pathognomonic signs of a number
of neurodegenerative diseases that includes Alzheimer’s disease, Huntington disease,
amyotrophic lateral sclerosis, Friedrich’s ataxia and Parkinson’s disease. Particularly relevant
for neurodegenerative processes is the relationship between mitochondria and iron. The
mitochondrion upholds the synthesis of iron–sulfur clusters and heme, the most abundant
iron-containing prosthetic groups in a large variety of proteins, so a fraction of incoming
iron must go through this organelle before reaching its ﬁnal destination. In turn, the
mitochondrial respiratory chain is the source of reactive oxygen species (ROS) derived
from leaks in the electron transport chain. The co-existence of both iron and ROS in
the secluded space of the mitochondrion makes this organelle particularly prone to
hydroxyl radical-mediated damage. In addition, a connection between the loss of iron
homeostasis and inﬂammation is starting to emerge; thus, inﬂammatory cytokines like
TNF-alpha and IL-6 induce the synthesis of the divalent metal transporter 1 and promote
iron accumulation in neurons and microglia. Here, we review the recent literature on
mitochondrial iron homeostasis and the role of inﬂammation on mitochondria dysfunction
and iron accumulation on the neurodegenerative process that lead to cell death in
Parkinson’s disease. We also put forward the hypothesis that mitochondrial dysfunction,
iron accumulation and inﬂammation are part of a synergistic self-feeding cycle that ends in
apoptotic cell death, once the antioxidant cellular defense systems are ﬁnally overwhelmed.
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INTRODUCTION
Iron is an essential element necessary for the normal devel-
opment of brain functions. Enzymes involved in neurotrans-
mitter synthesis that possess iron as a prosthetic group are
recognized targets of iron deﬁciency: monoamine oxidases A
and B involved in dopamine catabolism, tryptophan hydrox-
ylase, required for serotonin synthesis, tyrosine hydroxylase,
required for dopamine and norepinephrine synthesis, gluta-
mate decarboxylase involved in GABA synthesis and glutamate
transaminase involved in L-glutamate synthesis, all belong to this
group.
Abundant evidence shows that iron accumulation in particu-
lar areas of the brain is a hallmark of several neurodegenerative
disorders (Zecca et al., 2004; Andersen et al., 2013), although it is
uncertainwhether iron accumulation is a primary cause of the dis-
order or a consequence of a previous dysfunction. Increased levels
of iron promote cell death via hydroxyl radical formation, which
enhances lipid peroxidation, protein aggregation, glutathione con-
sumption, and nucleic acid modiﬁcation. We recently put forward
the hypothesis that iron accumulation, a process initiated by mito-
chondrial dysfunction, and the ensuing oxidative damage is part
of the execution step, i.e., the death process of affected neurons
(Núñez et al., 2012).
Mitochondrial dysfunction has long been associated with
several neurodegenerative diseases that include Alzheimer’s dis-
ease (AD), Huntington’s disease (HD), Parkinson’s disease (PD),
amyotrophic lateral sclerosis (ALS), and Friedrich’s Ataxia (FA;
Schapira and Cooper, 1992; Moreira et al., 2010; Grubman et al.,
2013). Mitochondrial dysfunction results in decreased ATP syn-
thesis, as well as in decreased synthesis of iron–sulfur clusters
(ISCs) and heme prosthetic groups. An association between mito-
chondrial dysfunction and mitochondrial iron accumulation has
been found only in FA (Delatycki et al., 1999; Huang et al., 2009),
although evidence for mitochondrial iron accumulation has been
reported in experimental models of PD (Liang and Patel, 2004;
Lee et al., 2009; Mena et al., 2011).
Inﬂammation in the central nervous system (CNS) is a con-
dition strongly associated with neuronal death in several neu-
rodegenerative disorders including PD and AD (Hirsch and
Hunot, 2009). Inﬂammation is characterized by the occur-
rence of reactive microglia and a massive production of pro-
inﬂammatory cytokines. These inﬂammatory processes trig-
ger a chain of events including increased production of
ROS and reactive nitrogen species (RNS), disruption of iron
metabolism and mitochondrial dysfunction, ﬁnally leading to
neurodegeneration.
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THE BASIS OF IRON TOXICITY
The ability of iron to exchange readily one electron underlies its
insertion in numerous catalytic processes found in living matter.
The iron atom has octahedral coordination chemistry; therefore,
it has six possible coordination bonds. Seminal work by Graf and
associates demonstrated that iron is redox-inactive only if all its
six coordination sites are stably bound. If one of the sites is free or
loosely bound, iron is redox-active and competent of undertaking
one-electron exchange reactions (Graf et al., 1984). It is notewor-
thy that Fe3+ complexeswith the chelators desferrioxamine,DTPA
or phytate at 1:10 (mol:mol) ratio result in redox-inactive iron
whereas Fe3+ chelation with NTA, EDTA, EGTA, ATP, CDTA or
bleomycin results in redox-active iron at the same 1:10 molar ratio
(Graf et al., 1984).
Iron is a paramagnetic element with two stable oxidation
states: 2+ and 3+. As mentioned above, both Fe2+ and Fe3+
establish coordination complexes with a great variety of ligands.
Iron complexes display a variety of reduction potentials, rang-
ing from very positive to negative values because of a basic
concept in coordination chemistry that establishes that the lig-
and modiﬁes the electron cloud surrounding the metal, thus
modifying its reduction potential. This versatility in reduction
potential allows for ﬁne-tuning between iron reduction potential
and the electron transfer process it catalyzes. It is estimated that
the predominant reduction potential for iron in the intracellu-
lar milieu of the cell is near zero V (Clark, 1960; Wood, 1988).
Many in vitro experiments conﬁrm iron-mediated production
of the hydroxyl radical (•OH), which arises from the following
reactions:
1. Fe2++O2 ↔ Fe3++O•−2 E0: − 0.43V; G = 41.5KJ
/
mol
2. O•−2 +2H+ → H2O2+O2E0: 0.55V; G = − 53.0KJ
/
mol
3. Fe2+ + H2O2 → Fe3++OH+•OH E0: 0.10V;
G = − 9.7KJ/mol
The thermodynamic sum of reactions 1–3 gives reaction
4:
4. 3Fe2+ + 2O2 + 2H+ → Fe3++OH−+•OH
G = − 21.2KJ/mol
The intracellular environment provides abundant reducing power
in the form of GSH (mM) and Asc (μM), which reduces Fe3+ to
Fe2+:
5. Fe3+ + GSH(Asc) → Fe2++GSSH(Asc • ) + H+E0 : 0.262;
G = − 25.3KJ/mol
Changes in free energy were calculated applying the equation
ΔG = −nFE0 (Joule/mol), in which n is the number of elec-
trons exchanged and F the Faraday constant. Reaction 1 values
were from (Pierre and Fontecave, 1999); Reaction 2, the half-cell
potential for H2O2 dismutation was considerer 0.45 V (Pierre and
Fontecave, 1999) and the reduction potential of the Fe3+/Fe2+
half-cell was considered 0 V (Wood, 1988); Reaction 3 (Fenton
reaction): E0 half-cell values from (Buettner, 1993; Buettner and
Schafer, 2000). Half-cell potentials for reaction 5 were obtained
from (Millis et al., 1993; Pierre and Fontecave, 1999). GSH:
reduced glutathione; GSSG: oxidized glutathione; Asc: ascorbate;
Asc•: ascorbate free radical.
The hydroxyl radical is considered one of the most reactive
species generated in biological systems, since its reaction rate
is only limited by diffusion, with rate constants in the 109–
1012 Mol−1 s−1 range (Davies, 2005). This molecule induces
irreversible damage to DNA, RNA, proteins, and lipids. Indeed,
the hydroxyl radical is believed to be the etiological agent for sev-
eral diseases and may be involved in the natural process of aging
(Lipinski, 2011).
The main components of cell iron homeostasis are the divalent
metal transporter 1 (DMT1), a Fe2+ transporter that brings iron
into the cell, the transferrin receptor 1 (TfR1) that brings iron
in through the endocytosis of Ferro-transferrin, the iron export
transporter ferroportin 1 (FPN1) and the cytosolic iron storage
protein ferritin. The expression of these proteins is transduc-
tionally regulated by the iron responsive element/iron regulatory
protein (IRE/IRP) system, which is activated when cells have
low iron levels, resulting in increased DMT1 and TfR1 levels
and decreased FPN1 and ferritin expression (Muckenthaler et al.,
2008).
In cells, iron in the 0.2–1.5 μM range is weakly complexed
to low-molecular weight substrates such as citrate, carboxylates,
amines, phosphate, nucleotides, GSH, and other molecules con-
forming the“cytosolic labile iron pool” (cLIP; Epsztejn et al., 1997;
Kakhlon andCabantchik, 2002; Petrat et al., 2002; Hider andKong,
2011). Iron in this pool is redox-active, cycling between the Fe+2
and Fe+3 forms, with prevalence of the reduced form because of
the reductive cytosol environment. This redox-active pool is suit-
able to experimental detection by the ﬂuorophore calcein, which
has higher afﬁnity for Fe3+ than for Fe2+ but since the reduction
potential for iron in the Fe-calcein complex is low, Fe3+ bound
to calcein is readily reduced in the intracellular environment,
resulting in decreased calcein ﬂuorescence (Petrat et al., 2002). In
cultured neuroblastoma cells the LIP represents about 3% of total
cellular iron under basal culture conditions, but this percentage
increases 3–4 fold, to μM concentrations, after exposure of cells
to high extracellular iron concentrations (Núñez-Millacura et al.,
2002; Núñez et al., 2004). In cell models, iron overload generates
increased lipid peroxidation, protein modiﬁcations and damage
to DNA, consistent with the production of the hydroxyl radical
(Mello-Filho and Meneghini, 1991; Núñez et al., 2001; Sochaski
et al., 2002; Zoccarato et al., 2005).
INFLAMMATORY CYTOKINES INDUCE THE PRODUCTION OF
RNS, ROS AND IRON ACUMULATION
Postmortem tissues from patients with AD, PD, HD, ALS or FA
show oxidative damage in the affected brain regions (Nunomura
et al., 1999; Barnham et al., 2004; Emerit et al., 2004). The asso-
ciation between inﬂammation and oxidative damage is mediated
by the release of RNS and ROS during the inﬂammatory pro-
cess. In particular, activated microglia have high levels of nitric
oxide synthase (NOS) and NADPH oxidase (NOX), two enzyme
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systems that mediate the increase in the oxidative tone induced by
inﬂammation.
Microglia, the brain-resident immune cells, are essential for
the generation of the inﬂammatory response. They are activated by
distress signals released fromneighboring cells, initiating an innate
response characterized by the production of pro-inﬂammatory
cytokines and, incidentally, phagocytosis (McGeer et al., 1988;
Colton and Wilcock, 2010). Indeed, many cases of AD and PD
are accompanied by a dramatic proliferation of reactive amoeboid
macrophages and activated microglia in the substantia nigra (SN)
or frontal cortex (McGeer et al., 1988; Possel et al., 2000; Kiyota
et al., 2009; Hewett and Hewett, 2012), together with high expres-
sion of pro-inﬂammatory cytokines (Bauer et al., 1991; Mogi et al.,
1994; Muller et al., 1998; Nagatsu, 2002; Hewett and Hewett,
2012).
Inducible NOS (iNOS, also called NOS-2), which is scarcely
expressed in the brain is induced during gliosis in pathological
situations including AD (Aliev et al., 2009) and PD (Dawson and
Dawson, 1998). Up-regulation of iNOS and of cyclo-oxygenase-1
and cyclo-oxygenase-2 in amoeboid microglia occurs in the SN of
human PD patients (Knott et al., 2000). A study on the levels of
iNOS mRNA in postmortem PD basal ganglia found a signiﬁcant
increase in iNOS expression in the dorsal two-thirds of the stria-
tum and in the medial medullary lamina of the globus pallidus,
accompanied by a reduction in iNOS mRNA expression in the
putamen (Eve et al., 1998).
Inﬂammatory mediators, including LPS and some cytokines
(TNF-α, IL-1β, and IFN-γ) induce the transcriptional activa-
tion of the iNOS gene in astrocytes and microglia via activation
of the transcription factors STAT1 and NF-kB (Grzybicki et al.,
1996; Possel et al., 2000; Hewett and Hewett, 2012). These factors
translocate to the nucleus and bind to response elements present
in the iNOS coding sequence. Upregulation of microglial iNOS
expression is also observed after administration of 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP; Liberatore et al., 1999;
Tieu et al., 2003; Kokovay andCunningham,2005;Yokoyama et al.,
2008). Interestingly, administration of MPTP produces signiﬁ-
cantly less neuronal loss in mice deﬁcient in iNOS compared to
their wild type counterparts (Dexter et al., 1986; Liberatore et al.,
1999; Dehmer et al., 2000). In the 6-hydroxidopamine (6-OHDA)
model, iNOS activity in the striatum induces neurodegeneration
in rats. Pretreatment with the iNOS inhibitor L-NAME blocks
amphetamine-induced rotations and signiﬁcantly restores striatal
dopamine (DA) levels in 6-OHDA treated rats (Barthwal et al.,
2001). In neuroinﬂammatory models of PD, iNOS also partici-
pates in nigral neurodegeneration. Injection of LPS induces iNOS
expression in the SN in a time- anddose-dependentmanner; iNOS
is present mainly in fully activated microglia with the charac-
teristic amoeboid morphology. Furthermore, LPS-induced loss
of dopaminergic neurons decreases signiﬁcantly by administra-
tion of an iNOS inhibitor (Arimoto and Bing, 2003; Singh et al.,
2005).
The iNOS enzyme is a relevant factor in the neurodegen-
erative process associated to AD. Early observations reported
increased iNOS and nitrotyrosine protein modiﬁcations in AD
brains, mainly in neuroﬁbrillary tangle-bearing neurons and neu-
ropil threads as well as in astrocytes (Vodovotz et al., 1996; Smith
et al., 1997; Wallace et al., 1997). Studies in transgenic mice over-
expressing amyloid beta precursor protein (APP) demonstrated
that several pathological changes such as vessel lesions, amyloid
deposition and mitochondrial DNA deletions, are associated with
the degree of NOS overexpression (Seyidova et al., 2004). Never-
theless, the APPsw/iNOS(−/−) mice, which express human APP
mutations on an iNOS knockout background, show increased
appearance of tau pathology, neuronal death, neuroinﬂammation
and behavioral deﬁcits compared with the parental APPsw mice
(Colton et al., 2008). This evidence indicates that in AD, the pro-
duction of NO can be protective or damaging, depending on the
levels of NO production.
The phagocyteNOX is themain regulated source of ROS gener-
ation. The catalytic component of the NOX complex is composed
by a family of multiple-pass transmembrane proteins, named
NOX1–4. The most studied, NOX2, also known as gp91phox or
phagocyte oxidase (PHOX), is highly expressed in innate immune
cells including microglia and it is most likely the predominant
NOX isoform expressed in astrocytes, while neurons express both
NOX2andNOX4 (Skalnik et al., 1991;NohandKoh,2000; Lavigne
et al., 2001; Abramov et al., 2004; Pawate et al., 2004). NOX2 forms
a complex with p67phox, p47phox, p40phox, and p22phox sub-
units. Several stimuli induce NOX2 complex priming, including
pro-inﬂammatory cytokines (TNF-α, IL-1β) and Toll-like recep-
tor (TLR) agonists like LPS, peroxynitrite and proteases. The
primed NOX2 complex requires yet additional activation to ini-
tiate substantial ROS production. PKC activators, growth factors,
complement protein C5a and G protein-coupled receptor agonists
generate a fully activeNOXcomplex (Yang et al., 2009,2013; Sareila
et al., 2011).
Activation of NOX also occurs in experimental models of PD
and AD. Treatment with MPTP results in increased synthesis of
the proinﬂammatory cytokine IL-1β and increased membrane
translocation of p67phox that is prevented byminocycline, a tetra-
cycline derivative that exerts multiple anti-inﬂammatory effects
(Wu et al., 2002). In addition, aging mice treated with MPTP
display an increase in gp91phox and 3-nitrotyrosine (L’Episcopo
et al., 2010; Huh et al., 2011). In agreement, gp91phox−/−
mice display decreased degeneration of dopaminergic neurons
induced by MPTP compared to wild type mice (Wu et al., 2003;
Zhang et al., 2004). The unilateral injection of 6-OHDA into the
right striatum of rats induces an increase of NOX1 and NOX2
both in the striatum and the SN. In concordance, dopamin-
ergic neuronal and TNF-α and IFN-γ induction triggered by
6-OHDA are abrogated in the gp91phox−/− or minocycline
treated mice (Hernandes et al., 2013). Additionally, striatal injec-
tion of 6-OHDA increases NOX1 expression in dopaminergic
neurons in rat SN, and also increases 8-oxo-dG content, a marker
of DNA oxidative damage. Moreover, NOX1 knockdown reduces
6-OHDA-induced oxidative DNA damage and dopaminergic
neuronal degeneration (Choi et al., 2012).
Microglia of AD subjects display activated NOX2, resulting
in the formation of ROS that are toxic to neighboring neu-
rons (Shimohama et al., 2000). In conjunction, an increment in
NOX1 and NOX3 mRNA levels in the frontal lobe tissue from
AD brains was reported, suggesting the participation of other
NOX family members in AD neuropathology (de la Monte and
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Wands, 2006). Recently, increased NOX-dependent ROS produc-
tion in the superior/middle temporal gyri at the earliest clinical
manifestations of disease, but not in late-stage AD, was reported
(Bruce-Keller et al., 2010). Genetic inactivation of NOX2 in 12- to
15-month-old mice overexpressing the APPsw mutation (Tg2576
mice) results in reduced oxidative damage and rescues both the
vascular and behavioral alterations observed in Tg2576 mice (Park
et al., 2008). Studies done in cell cultures replicated the post-
mortem and animal ﬁndings on oxidative damage driven by NOX
activation. Experiments using co-cultures of neuronal and glial
cells found that Aβ acts preferentially on astrocytes but causes
neuronal death (Abramov et al., 2004; Abramov and Duchen,
2005). The Aβ peptide causes transient increases in cytoplasmic
calcium in astrocytes, associated with increased ROS genera-
tion, glutathione depletion and mitochondrial depolarization.
Neuronal death after Aβ exposure was reduced both by NOX
inhibitors and in the gp91phox knockout mice. These data are
consistent with a sequence of events in which Aβ activates NOX
in astrocytes by increasing cytoplasmic calcium, generating an
oxidative burst that causes the death of neighboring neurons
(Abramov et al., 2004; Abramov and Duchen, 2005; Park et al.,
2008).
Inﬂammatory conditions such as those found in neurodegener-
ative diseases also affect iron homeostasis through transcriptional
modiﬁcation of iron transporters. In this context, the observation
that the transcription factor NFκB induces DMT1 expression is
highly relevant for understanding the relationshipbetween inﬂam-
mation and iron homeostasis (Paradkar and Roth, 2006). We
recently reported that the pro-inﬂammatory cytokines TNF-α, IL-
6 and the TLR4 agonist LPS directly regulate DMT1mRNA and
protein levels and induce a transient decrease inFPN1protein, thus
generating an increment of iron content in neurons and microglia
(Urrutia et al., 2013). Supporting the results described above, a
recent study using primary cultures of ventral mesencephalic neu-
rons demonstrated that TNF-α or IL-1β induce an increment
in DMT1 and TfR1 protein levels, together with a reduction of
FPN1 levels, resulting in an increase in ferrous iron inﬂux and
decreased iron efﬂux inneurons (Wang et al., 2013). These ﬁndings
were replicated in systemic tissues. Treatment of mouse spleno-
cyte with LPS down-regulates the expression of FPN1 through a
signaling mechanism mediated by TLR4 (Yang et al., 2002). More-
over, stimulation of macrophage cell lines with IFN-γ, TNF-α or
LPS results in increased IRE-binding activity of IRP1 and IRP2,
and increased DMT1 mRNA expression (Mulero and Brock, 1999;
Wardrop andRichardson, 2000; Ludwiczek et al., 2003;Wang et al.,
2005).
Considering that NFκB activation takes place downstream of
TNF-α, IL-1 and LPS signaling pathways (Teeuwsen et al., 1991;
Rothwell and Luheshi, 2000; Hanke and Kielian, 2011), inﬂamma-
tory stimuli may induce DMT1 expression via NFκB activation.
Indeed, TNF-α was detected in glial cells in the SN of PD
patients but not in control subjects, together with immunore-
activity for TNF-α receptors in dopaminergic neurons of both
control and PD patients (Boka et al., 1994). These ﬁndings are
suggestive of a circuit in which activation of nigral microglia
results in TNF-α secretion, which might increase iron uptake
by dopaminergic neuron via NF-κB-induced DMT1 expression.
Indeed, an increase in the nuclear immunoreactivity of NFκB
has been observed in PD brains or in animal models for this
disease (Hunot et al., 1997), so it is possible that activation of
NF-κB via inﬂammatory stimuli contributes to iron accumulation
in PD. Accordingly, inﬂammation could induce the production of
hydroxyl radical trough the activation of two parallel pathways: (i)
through DMT1-mediated increase of intracellular iron levels and
(ii) through increased hydrogen peroxide levels mediated by NOX
activation.
A positive feedback loop can be established between ROS/RNS
and inﬂammatory cytokines. ROS induce intracellular signaling
pathways that result in the activation of transcriptional factors
like NF-kB, AP-1 and Nrf-2, which regulate the expression of pro-
inﬂammatory mediators such as Cox-2, MCP-1, IL-6, TNF-α, IL-
1α, and IL-1β (Hensley et al., 2000; Thannickal and Fanburg, 2000;
Ueda et al., 2002; Ridder and Schwaninger, 2009; Kitazawa et al.,
2011; Guo et al., 2012; Kawamoto et al., 2012; Phani et al., 2012;
Song et al., 2012; Zhang et al., 2012; Tobon-Velasco et al., 2013).
These cytokines and chemokines, in turn, stimulate a cascade of
events leading to increased oxidative stress via iNOS and NOX
activation.
INFLAMMATORY CONDITIONS INDUCE MITOCHONDRIAL
DYSFUNCTION
The study of the relationship between inﬂammation and mito-
chondrial activity in the CNS is incipient. Intrastriatal injection
of LPS induces mitochondrial dysfunction, microgliosis, iron
accumulation and progressive degeneration of the dopamine
nigro-striatal system (Zhang et al., 2005; Hunter et al., 2007,
2008; Choi et al., 2009), as observed in PD pathology. Similarly,
cytokines such as IL-1β decrease mitochondrial activity through
the production of NO in cardiomyocytes (Tatsumi et al., 2000).
Several reports indicate that TLRs regulatemitochondrial activ-
ity. Activation of TLR3 results in reduction of mitochondrial
oxygen consumption mediated by opening of the permeability
transition pore (Djafarzadeh et al., 2011). In co-cultures of corti-
cal neurons with microglial cells, the TLR4 agonist LPS promotes
decreased oxygen consumption and oxidative stress, with the sub-
sequent nigral dopaminergic neuronal death in a rat model of
inﬂammation (Xie et al., 2004; Hunter et al., 2007). Although these
studies strongly suggest a link between TLRs and mitochondria
dysfunction, further studies should clarify the molecular mecha-
nisms involved and its relevance to particular neurodegenerative
processes.
The production of ROS and RNS affects mitochondrial activ-
ity through destabilization of the ISCs (Cassina and Radi, 1996;
Brown and Borutaite, 2004). The free radical superoxide damages
and/or oxidizes 4Fe-4S clusters, which results in the formation
of the “null” 3Fe-4S center form (Flint et al., 1993; Haus-
laden and Fridovich, 1994; Gardner et al., 1995; Bouton et al.,
1996). Additionally, NO reacts with 4Fe-4S clusters generating
[(NO)2Fe(SR)2] type complexes that inactivate several mitochon-
drial iron–sulfur enzymes including proteins which compose
the electron transport chain (Drapier, 1997; see below). The
above data are consistent with the notion that inﬂammation,
ROS/RNS production, and mitochondrial dysfunction are linked
processes.
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Additionally, recent evidence shows that under certain
conditionsmitochondria canmodulate the immune response. The
mitochondrial protein MARCH5 (an ubiquitin E3 ligase constitu-
tively expressed in the mitochondrion outer membrane) positively
regulates TLR7 and TLR4 signaling, resulting in NFκB activation
and expression of the NFκB-responsive genes IL-6 and TNF-α
(Shi et al., 2011). In addition, activation of TLR1, TLR2 and TLR4
results in augmented mitochondrial ROS production by inducing
translocation to mitochondria of TRAF6 (TLR signaling adaptor,
tumor necrosis factor receptor-associated factor 6), which leads to
the engagement and ubiquitination of ECSIT (evolutionarily con-
served signaling intermediate in Toll pathways), a protein required
for efﬁcient assembly of mitochondrial complex I (West et al.,
2011). It remains to be demonstrated whether this mechanism
is operative in CNS cells.
Interestingly,mitochondrial ROS (mtROS) could arguably acti-
vate the inﬂammatory response. In vascular endothelium, mtROS
act as intermediate signalingmolecules to trigger production of IL-
6 (Lee et al., 2010). In addition, patients with the autoinﬂamma-
tory disorder TRAPS (tumor necrosis factor receptor-associated
periodic syndrome), exhibit altered mitochondrial function with
enhanced mtROS generation and increased production of IL-6,
TNFα, and IL-1β; decreasing mtROS levels by the general antioxi-
dant N-acetylcysteine effectively reduces inﬂammatory cytokine
production after LPS stimulation (Bulua et al., 2011). These
results point to novel pathways that link inﬂammation to mtROS
production.
In summary, inﬂammation induces ROS production and mito-
chondrial dysfunction generating a self-feeding cycle that could
lead to neurodegeneration in diseases where inﬂammation and
oxidative damage are prevalent (Figure 1). In this cycle, [1] inﬂam-
mation induces ROS and RNS generation by activation of the
NOX and iNOS enzymes (Possel et al., 2000; Sareila et al., 2011;
Hewett and Hewett, 2012); [2] in turn, ROS/RNS induce the
FIGURE 1 | Inflammation causes ROS/RNS production, mitochondrial
dysfunction, and iron accumulation. Inﬂammation, oxidative damage,
and mitochondrial dysfunction are common features of neurodegenerative
diseases. A complex net of relationships connect these features, which
through feedback mechanisms contribute to the evolvement of neuronal
death (see text for details).
expression of inﬂammatory cytokines (Baeuerle andHenkel, 1994;
Sen and Packer, 1996). [3] Additionally, inﬂammation induces
mitochondrial dysfunction through activation of TLR signaling
(Xie et al., 2004; Djafarzadeh et al., 2011). [4] ROS in turn induce
mitochondrial dysfunction by destabilizing ISCs, which results
in the inactivation of several mitochondrial iron–sulfur enzymes
(Cassina and Radi, 1996; Brown and Borutaite, 2004). [5] Mito-
chondrial dysfunction leads to IRP1 activation and increased iron
uptake (Lee et al., 2009; Mena et al., 2011). [6] Iron increases
oxidative damage by transforming mild oxidative molecules like
superoxide and hydrogen peroxide into the hydroxyl radical (Graf
et al., 1984). [7] Electron transport chain inhibition increases
ROS production by electron leak (Drose and Brandt, 2012), and
arguably could modulate the innate immune response by TLR sig-
naling regulation (Shi et al., 2011) [8]. Finally, [9] inﬂammation
is likely to cause iron accumulation through induction of DMT1
expression and transient ferroportin decrease (Urrutia et al., 2013;
Wang et al., 2013).
MITOCHONDRIAL DYSFUNCTION, INFLAMMATION AND
IRON ACCUMULATION IN THE DEATH OF NEURONS IN PD
Mitochondria have a key role in iron metabolism in association
with the synthesis of ISCs and heme, prosthetic groups that
are vital for cell function. Iron complexes are particularly rel-
evant components of the electron transport chain: 12 proteins
contain ISCs and eight proteins contain heme in their active cen-
ters (Rouault and Tong, 2005). Other proteins that have ISCs
are the Krebs cycle enzymes aconitase and succinate dehydro-
genase, ribonucleotide reductase, an enzyme that catalyzes the
formation of deoxyribonucleotides from ribonucleotides, and fer-
rochelatase, involved in the addition of Fe to porphyrin IX during
heme synthesis. We refer the reader to
Mitochondria have a redox-active iron pool (Petrat et al., 2001);
an increase in this pool directly associates with an increase in
oxidative damage and with calcium-dependent changes in the
mitochondrial permeability transition pore (Pelizzoni et al., 2011;
Kumfu et al., 2012; Zhang and Lemasters, 2013). Thus, cells
must regulate tightly their mitochondrial Fe levels because an
iron shortage affects numerous processes that have iron as a co-
factor, including the electron transport chain, whereas an excess of
redox-active iron promotes the generation of the noxious hydroxyl
radical. How mitochondria regulate their iron content and what,
if any, is the interplay between cytoplasmic and mitochondrial
iron are incipient but highly relevant subjects to understand the
mechanisms of mitochondrial dysfunction in neurodegenerative
diseases.
There is increasing evidence that mitochondrial dysfunction
plays an important role in the development of neurodegenerative
diseases such as AD, HD, FA, and PD (Enns, 2003; Mandemakers
et al., 2007; Sas et al., 2007; Gogvadze et al., 2009; Jellinger, 2009).
Imbalances in ROS and ATP levels derived from mitochondrial
dysfunction affect neurons particularly, given their dependence
on ATP to propagate electrical signals, maintain ionic gradi-
ents, and facilitate anterograde and retrograde transport along
axons (Su et al., 2013). The involvement of mitochondrial dys-
function in the pathophysiology of PD was noted very early in
the study of the disease. Evidence of mitochondrial dysfunction
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in PD began in the eighties, when, after an intravenous injection
of illicit drugs, four college students developed marked Parkin-
sonism. Analysis of the substances injected revealed the presence
of MPTP, a compound metabolized by astrocytes into 1-methyl-
4-phenylpyridinium (MPP+), which is then released into the
extracellular space. MPP+ is taken up selectively by dopaminergic
(DA) neurons where it inhibits mitochondrial complex I (Heikkila
et al., 1984; Langston et al., 1984; Nicklas et al., 1985; Gautier et al.,
2013). Further evidence showed that complex I activity and the
number of complex I subunits are decreased in postmortem tis-
sue of idiopathic PD patients (Bindoff et al., 1989; Mizuno et al.,
1989; Schapira et al., 1989). These results strongly suggest that
mitochondrial dysfunction is a pathognomonic sign in the patho-
physiology of PD. Reduced complex-I activity and an increased
susceptibility to MPP+ were also observed in cybrids contain-
ing mitochondrial DNA from PD patients (Swerdlow et al., 1996,
2001; Gu et al., 1998a), suggesting the presence of mitochondrial
DNA-encoded defects in PD (Chaturvedi and Flint Beal, 2013).
Additionally, in the epidemiology ﬁeld, the use in farming of the
highly lipophilic pesticide rotenone, a potent inhibitor of mito-
chondrial complex I, has been linked to a higher incidence of PD
in agricultural workers (Betarbet et al., 2000; Tanner et al., 2011;
Pezzoli and Cereda, 2013).
Mitochondrial complex I is a major source of ROS. Complex
I from mitochondria of PD patients contain 47% more protein
carbonyls localized to catalytic subunits and a 34% decrease in
complex I 8-kDa subunit. NADH-driven electron transfer rates
through complex I inversely correlate with complex I protein oxi-
dation status and with the reduction in the 8-kDa subunit protein
levels (Keeney et al., 2006).
Knowledge on the mechanisms that associate mitochondrial
dysfunction and iron dyshomeostasis in PD is incipient. Treatment
of SH-SY5Y dopaminergic neuroblastoma cells with mitochon-
drial complex I inhibitors such as rotenone or MPP+ results in
FIGURE 2 | A positive feedback loop in the death of neurons in PD.
Inhibition of mitochondrial complex I by endogenous or exogenous toxins or
mutations in PD genes Parkin, Pink 1, Alpha-synuclein, DJ-1 or LRRK2
generates a multifactorial positive feedback loop. In this loop, complex I
inhibition results in iron accumulation driven by decreased Fe-S cluster
synthesis, IRP1 activation, increased DMT1 and TfR1 expression and
decreased FPN1 expression, increased ROS levels and decreased
glutathione levels. Both increased oxidative stress and low GSH levels
further inhibit complex I activity. Another input to this cycle is contributed
by inﬂammatory cytokines that through self-feeding cycles induce
mitochondrial dysfunction, increased ROS/RNS production and iron
accumulation mediated by the transcriptional regulation of DMT1 and FPN1
(see text). The cumulative oxidative damage ﬁnally results in apoptotic death
(see text for details).
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ROS production and increased mitochondrial iron uptake (Lee
et al., 2009; Mena et al., 2011). Moreover, inhibition of com-
plex I by rotenone decreases the activity of three ISC-containing
enzymes: mitochondrial and cytoplasmic aconitases and xanthine
oxidase, and decreases the ISC content of glutamine phosphori-
bosyl pyrophosphate amidotransferase (Mena et al., 2011). The
reduction in cytoplasmic aconitase activity is associated with an
increase in iron regulatory IRP1 mRNA binding activity and
with an increase in the mitochondrial labile iron pool (Mena
et al., 2011). Since IRP1 activity post-transcriptionally regulates
the expression of iron import proteins, ISC synthesis inhibition
may result in a false iron deﬁciency signal with the ensuing iron
accumulation.
Considering the evidence discussed, we propose that inhibition
of mitochondrial complex I by endogenous and/or exogenous tox-
ins or by inﬂammatory processes resulting from trauma or other
causes, engage a vicious cycle of increased oxidative stress and
increased iron accumulation (Figure 2). In this scheme, inhibi-
tion of mitochondrial complex I by endogenous or exogenous
toxins, or because of mutations in PD genes Parkin, Pink 1, alpha-
synuclein, DJ-1 or LRRK2 (Langston and Ballard, 1983; Schapira
et al., 1990; Hsu et al., 2000; Silvestri et al., 2005; Martin et al.,
2006; Junn et al., 2009; Angeles et al., 2011; Mena et al., 2011),
results in decreased electron transport chain activity [1] and the
ensuing ATP synthesis decrease and ROS increase [2]. Decreased
ATP levels impairs ISC synthesis that results in decreased activity
of ISC-containing proteins and increased mRNA binding activ-
ity of the iron homeostasis protein IRP1. IRP1 activation leads
to increased DMT1 and TfR1 expression (Lee et al., 2009; Mena
et al., 2011) [3] and the ensuing iron accumulation (Asenjo, 1968;
Dexter et al., 1987; Faucheux et al., 2003; Michaeli et al., 2007)
[4]. Increased ROS and increased redox-active iron promotes the
consumption of intracellular reductants such as GSH and ascor-
bate (Perry et al., 1982; Ehrhart and Zeevalk, 2003; Núñez et al.,
2004; Jomova et al., 2010) [5], resulting in a further decrease in
mitochondrial activity and ISC synthesis (Harley et al., 1993; Gu
et al., 1998b; Jha et al., 2000; Chinta et al., 2007; Danielson et al.,
2011). Another input to this cycle is contributed by inﬂammatory
cytokines liberated by activated microglia and astrocytes (Mogi
et al., 1994) [6], which enhance mitochondrial dysfunction (Tat-
sumi et al., 2000; Xie et al., 2004; Hunter et al., 2007; Djafarzadeh
et al., 2011) [7], increase ROS production (Grzybicki et al., 1996)
[8] and increase iron accumulation by modifying the expres-
sion of the iron transporters DMT1 and FPN1 (Urrutia et al.,
2013; Wang et al., 2013) [9]. As discussed in the text, increased
ROS back-feed the production of cytokines. Increased ROS lev-
els, in particular increased hydroxyl radical generation, produces
increased oxidative damage, which is counteracted by antioxidant
defenses [10]. In time, the positive feedback loop of mitochondrial
dysfunction, iron dyshomeostasis and inﬂammation results in
alpha-synuclein aggregation, proteasomal dysfunction, changes in
mitochondrial ﬁssion/fusion dynamics, opening of the mitochon-
drion PTP, increased cytoplasmic cytochrome c and activation
of death pathways [11]. Debris and toxins from dying neurons
enhance the activation of glial cells, which contributes to the
inﬂammatorynetwork (Zecca et al., 2008;Hirsch andHunot,2009;
Gao et al., 2011) [12].
In summary, because of the innate interconnectivity of mito-
chondrial complex I dysfunction, iron accumulation, oxidative
stress, and inﬂammation, probably the initiation of any one of
these factors will induce or enhance the others through the gener-
ation of a positive feedback loop that in time will end in apoptotic
neuronal death. Still unanswered is the question of why neurons of
the SNc are so particularly prone to carry-on this cycle. On exam-
ination of this cycle, several therapeutic targets come to mind.
Its intervention should result in prolonged life of the affected
neurons.
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